

Contact: Spencer Sias (650) 424-5782
Vice President of Corporate Communications &
Investor Relations
Varian Medical Systems, Inc.

* All data as of January 1, 2010

NYSE Symbol: VAR	Stock Price : \$46.85	<u>Company Officers</u>
Market Capitalization: \$5.8 billion	52-Week Range: \$27.10 - \$47.78	Timothy E. Guertin, President/CEO
Basic Shares Outstanding: 124 mm	Avg. Daily Volume: 975,908 (3 mo.)	Elisha W. Finney, SVP/CFO
Institutional Ownership¹:	Q110 Revenues/EPS: \$541 mm / \$0.63	Robert H. Kluge, SVP/X-Ray Products
591 institutions / 94.9%	Employees: 5,000	John W. Kuo, VP, General Counsel
Management Ownership: 4.0%	Fiscal Year Ends: 10/01/10	Dow R. Wilson, EVP/Oncology Systems

Largest Institutional Owners¹

Sands Capital Mgmt. LLC	State Street Global Advisors (SSgA)
Harris Associates, Inc.	Chieftain Capital Mgmt., Inc.
Vanguard Group, Inc.	Franklin Advisers, Inc.
Blackrock Fund Advisors	TCW Investment Mgmt. Co.
Thornburg Investment Mgmt., Inc.	Generation Investment Mgmt., LLP

¹ Source: 01/01/10 Ipreo

² Initiated coverage 06/23/09

³ Initiated coverage 01/05/10

Financial Analyst Coverage

Barrington Research	Charley Jones
Citigroup	Amit Bhalla
Jefferies & Co.	Joshua Jennings ³
JP Morgan Securities	Tycho Peterson
Lazard Capital Markets	Sean Lavin, MD
Needham & Co.	Dalton Chandler
Oppenheimer	Amit Hazan
Robert W. Baird & Co. ²	Jeff Johnson
Soleil Securities	Junaid Husain

Company Background

Varian Medical Systems, Inc., (NYSE: VAR) serves the medical equipment market as the world's leading manufacturer of equipment, accessories, and software for treating cancer and other medical conditions with radiotherapy and radiosurgery. It is also the premier supplier of X-ray tubes and flat panel image detectors for filmless X-rays as well as imaging component products for security and inspection. The company has 5,100 employees in more than 79 facilities around the world. Business units include:

Oncology Systems:

- This unit is the world's largest supplier of radiotherapy, radiosurgery and brachytherapy products for treatment of cancer and neurological conditions. It manufactures, sells, and services linear accelerators and ancillary products for treatment planning, quality assurance, imaging and image processing, record management, and clinical administration. Thousands of patients around the world are treated daily on Varian products. Oncology Systems works closely with healthcare professionals in clinics, hospitals, and universities worldwide, addressing their requirements for continually improving treatment efficacy and cost containment.

X-Ray Products:

- This business unit is the world's premier independent supplier of X-ray generating tubes and flat panel digital image detectors for generating filmless X-ray images. It serves major original equipment manufacturers in the diagnostic imaging industry and replacement tube distributors. The business provides the industry's broadest selection of X-ray tubes and panels for the most advanced CT scanning, radiographic, mammographic, and other diagnostic applications. These products are expressly designed for high-resolution imaging, rapid examination, high patient throughput, long tube life, and cost efficiency.

Other

- The Company's "Other" category combines the Varian Particle Therapy (VPT) unit, Security and Inspection Products (SIP) unit, and Gintzon Technology Center (GTC). VPT supplies integrated hardware and software products for proton therapy. The SIP unit supplies linear accelerators, detectors, and software for generating and analyzing high energy x-rays used for industrial inspection and cargo screening in ports of entry and at borders. The GTC acts as the Company's research and development facility and conducts some contract research.

Varian Medical Systems Financial Overview

Consolidated Statements of Earnings

(Dollars in millions, except per share amounts)	Fiscal Year Ended			First Quarter Ended (Unaudited)		
	Oct 2, 2009	Sept 26, 2008	% Growth	Jan 1, 2010	Jan 2, 2009	% Growth
Revenues:						
Oncology Systems	\$ 1,797.8	\$ 1,671.8	8%	\$ 430.1	\$398.2	8%
X-Ray Products	331.7	305.2	9%	91.4	86.1	6%
Other	84.6	92.7	(9%)	19.4	24.4	(20%)
Total Revenues	2,214.1	2,069.7	7%	540.9	508.7	6%
Operating costs and expenses:						
Cost of revenues	1,253.6	1,192.2		299.9	289.7	
Research and development	147.4	135.6		38.4	37.0	
Selling, general and administrative	339.0	322.5		83.5	83.3	
Total operating costs & expenses	1,740.0	1,650.3		421.8	410.0	
Operating earnings	474.1	419.4		119.1	98.7	
Interest income/(expense), net	0.5	6.6		(0.3)	1.4	
Earnings from continuing operations before taxes	474.6	426.0		118.8	100.1	
Taxes on earnings	143.1	130.7		40.0	30.5	
Earnings from continuing operations	331.5	295.3		78.8	69.6	
Loss from discontinued operations – net of taxes ⁽¹⁾	(12.5)	(15.8)		-	(0.8)	
Net earnings	\$ 319.0	\$ 279.5		\$ 78.8	\$ 68.8	
Net earning per share – Diluted						
Continuing operations	\$ 2.65	\$ 2.31		\$ 0.63	\$ 0.56	
Discontinued operations ⁽¹⁾	(0.10)	(0.12)		-	(0.01)	
Net earnings per share	\$ 2.55	\$ 2.19		\$ 0.63	\$ 0.55	

⁽¹⁾ The operating results of ACCEL Research Instruments are classified as discontinued operations for all periods presented.


Key Balance Sheet Data

(Dollars in thousands)	Oct, 2, 2009	Sept. 26, 2008
Working capital	\$ 830,131	\$ 612,724
Total assets	\$2,308,248	\$1,975,512
Stockholders' equity	\$1,311,783	\$1,027,185


Revenue by Region (FY2009)

North America 50%
Rest of World 50%


Revenues
(Dollars)




Operating Costs and Expenses
(Dollars)



Earnings Before Taxes
(Dollars)



Net Earnings
(Dollars)



Note: The above charts reflect results from continuing operations.

Investor Relations Contacts:

Elisha W. Finney, Senior Vice President, CFO, 650.424.6803(p) elisha.finney@varian.com
 Spencer R. Sias, Vice President, Investor Relations, 650.424.5782 (p) spencer.sias@varian.com
 Neil Madle, Director, Investor Relations Europe, 44 (0)1293.60.1270 (p) neil.madle@varian.com

Note: This document contains summary financial information. Please refer to Varian's Form 10-K, Form 10-Q, and financial press releases for more detailed financial information. Except for information packet requests, the Company does not respond to investor inquiries submitted via e-mail.